Santhera Pharmaceuticals (SPHDF) News Today $9.42 0.00 (0.00%) (As of 12/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisChartHeadlinesShort Interest All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Santhera Pharmaceuticals: Buy Rating Affirmed Amidst Key Approvals and Strategic Partnerships Boosting Market ExpansionDecember 21 at 3:57 AM | markets.businessinsider.comSanthera Announces Approval in Hong Kong for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular DystrophyDecember 20 at 8:53 AM | uk.finance.yahoo.comSanthera Announces Approval from China’s NMPA for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular DystrophyDecember 11, 2024 | uk.finance.yahoo.comSanthera Receives Positive Recommendation from NICE for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular DystrophyDecember 10, 2024 | uk.finance.yahoo.comSanthera Gets Positive Recommendation From NICE For AGAMREE - Quick FactsDecember 10, 2024 | markets.businessinsider.comSanthera Enters into Exclusive Supply Agreement for AGAMREE® (Vamorolone) with Ali Al Suwaidi Trading Establishment (ASTE) in QatarNovember 13, 2024 | markets.businessinsider.comSanthera: LIONHEART Study Confirms Vamorolone's Unique Role As Mineralocorticoid Receptor AntagonistOctober 1, 2024 | markets.businessinsider.comSanthera Pharmaceuticals Holding (SANN)September 27, 2024 | uk.investing.comSanthera Announces Acceptance by Swissmedic of Marketing Authorization Application for AGAMREE® (vamorolone) in Duchenne Muscular DystrophySeptember 25, 2024 | finance.yahoo.comSanthera Pharma H1 Net Loss Narrows, Revenues ClimbSeptember 12, 2024 | markets.businessinsider.comSanthera Enters into an Exclusive Distribution Agreement with GENESIS Pharma for AGAMREE® (Vamorolone) in Central and Eastern EuropeSeptember 10, 2024 | finance.yahoo.comSanthera Pharma Partners With GENESIS Pharma For AGAMREE Distribution In Central And Eastern EuropeSeptember 10, 2024 | nasdaq.comSanthera Closes Financings and Secures Funds to Reach Break-Even Expected in 2026August 13, 2024 | finance.yahoo.comSanthera Pharmaceuticals Holding AG: Santhera Publishes Annual Report 2023May 28, 2024 | finanznachrichten.deSanthera Publishes Annual Report 2023May 28, 2024 | finance.yahoo.comSanthera : Vamorolone NDA Accepted For Priority Review By China' NMPA In Duchenne Muscular DystrophyMarch 27, 2024 | markets.businessinsider.comSanthera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Granted Priority Review by China’s NMPAMarch 27, 2024 | finance.yahoo.comSanthera Announces Publication of Efficacy, Safety and Tolerability Data with Vamorolone (AGAMREE®) in Patients with Duchenne Muscular Dystrophy in NeurologyFebruary 14, 2024 | finance.yahoo.comSanthera Pharmaceuticals Holding AG 0QN1February 3, 2024 | morningstar.comSanthera Pharmaceuticals Holding AG (SANN.SW)January 31, 2024 | finance.yahoo.comSanthera Launches AGAMREE® (Vamorolone) in Germany as First Market for the Treatment of Duchenne Muscular DystrophyJanuary 15, 2024 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Santhera Pharmaceuticals Holding (OtherSPHDF), Ironwood Pharma (IRWD) and Cytokinetics (CYTK)January 12, 2024 | markets.businessinsider.comSanthera Receives Approval for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy in the United KingdomJanuary 12, 2024 | finance.yahoo.comSanthera’s AGAMREE® (Vamorolone) Approved in the European Union for the Treatment of Duchenne Muscular DystrophyDecember 18, 2023 | finance.yahoo.comSanthera Appoints Executive Committee Members as it Transitions into Commercial StageDecember 7, 2023 | finance.yahoo.comSanthera Receives U.S. FDA Approval of AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular DystrophyOctober 27, 2023 | finance.yahoo.comUS FDA approves Santhera's Duschenne drugOctober 26, 2023 | reuters.comSanthera: Europe's CHMP Issues Positive Opinion For AGAMREE To Treat Duchenne Muscular DystrophyOctober 13, 2023 | markets.businessinsider.comPositive European Approval Outlook for Santhera’s AGAMREE Bolsters Buy Rating: Potential Milestone for DMD TreatmentOctober 13, 2023 | markets.businessinsider.comSanthera Receives Positive CHMP Opinion Recommending Approval of AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular DystrophyOctober 13, 2023 | finance.yahoo.comSanthera Pharmaceuticals reports 1H resultsSeptember 8, 2023 | seekingalpha.comSanthera Pharmaceuticals Holding AG (VTX:SANN) Is About To Turn The CornerSeptember 8, 2023 | finance.yahoo.comSanthera Announces Half-Year 2023 Financial Results and Provides Corporate UpdateSeptember 7, 2023 | finance.yahoo.comSanthera Completes Divestment of Raxone®/Idebenone Business to Chiesi GroupJuly 31, 2023 | benzinga.comH.C. Wainwright Keeps Their Buy Rating on Santhera Pharmaceuticals Holding (SPHDD)July 31, 2023 | markets.businessinsider.comSanthera Pharmaceuticals Holding AG: Santhera Publishes Timeline of the Reverse Share SplitJune 29, 2023 | finanznachrichten.deSanthera Publishes Timeline of the Reverse Share SplitJune 29, 2023 | finance.yahoo.comSanthera Pharmaceuticals Holding AG: Shareholders Approve all Board Proposals at Today's Annual General MeetingJune 27, 2023 | finanznachrichten.deShareholders Approve all Board Proposals at Today’s Annual General MeetingJune 27, 2023 | finance.yahoo.comCatalyst (CPRX) to Gain DMD Drug Licensing Rights From SantheraJune 21, 2023 | msn.comCatalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera PharmaceuticalsJune 20, 2023 | finance.yahoo.comSanthera Grants North America License For Vamorolone To Catalyst PharmaJune 20, 2023 | markets.businessinsider.comSanthera Grants Exclusive North America License for Vamorolone to Catalyst Pharmaceuticals in Deal Valued at up to USD 231 Million Plus RoyaltiesJune 20, 2023 | finance.yahoo.comSanthera Publishes Agenda for its Annual General MeetingJune 6, 2023 | finance.yahoo.comSanthera Pharmaceuticals GAAP EPS of -CHF1.17June 2, 2023 | seekingalpha.comSanthera Pharmaceuticals Holding AG: Santhera Publishes Annual Report 2022June 1, 2023 | finanznachrichten.deSanthera Publishes Annual Report 2022May 31, 2023 | finance.yahoo.comSanthera -- A Duchenne Drug With Positive Study Results That Few Know AboutMay 24, 2023 | thestreet.comSanthera Drug Wins European Approval for Rare Blindness DiseaseMay 13, 2023 | thestreet.comSanthera Announces Preliminary Unaudited 2022 Annual Results Ahead of Full Report Publication by End of May and Provides Corporate UpdateApril 27, 2023 | finance.yahoo.com Get Santhera Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SPHDF and its competitors with MarketBeat's FREE daily newsletter. Email Address Has Trump Finally Gone Too Far? (Ad)Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news. Register For The Webinar To Discover SPHDF Media Mentions By Week SPHDF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SPHDF News Sentiment▼0.820.60▲Average Medical News Sentiment SPHDF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SPHDF Articles This Week▼20▲SPHDF Articles Average Week Get Santhera Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SPHDF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AGNPF News AKBLF News DRTSW News APLMW News ARNI News ASPHF News ASCLF News AVCTF News AWKNF News AXIM News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:SPHDF) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Santhera Pharmaceuticals Holding AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Santhera Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SPHDF Stock Alerts